Compare ZH & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZH | BDTX |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 295.1M | 171.9M |
| IPO Year | 2021 | 2020 |
| Metric | ZH | BDTX |
|---|---|---|
| Price | $2.99 | $2.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.67 |
| AVG Volume (30 Days) | 153.2K | ★ 1.8M |
| Earning Date | 05-26-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.57 | $1.93 |
| 52 Week High | $5.55 | $4.94 |
| Indicator | ZH | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.44 | 42.30 |
| Support Level | $2.57 | $2.28 |
| Resistance Level | $3.82 | $2.47 |
| Average True Range (ATR) | 0.12 | 0.36 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 4.08 | 7.27 |
Zhihu Inc is engaged in the operation of one online content community which monetizes through paid membership services, marketing services and other services in the People's Republic of China. It is an online content community where people come to find solutions, make decisions, seek inspiration, and have fun. Its community supports discussions ranging from everyday consumer decisions, such as purchasing products or planning travel, to more specialized areas on professional knowledge, technological developments including artificial intelligence and academic topics. It operates in single segment and its revenues are derived from within the PRC.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.